162 related articles for article (PubMed ID: 25989503)
1. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.
Nobel YR; Goldberg DS
Transplantation; 2015 Nov; 99(11):2341-6. PubMed ID: 25989503
[TBL] [Abstract][Full Text] [Related]
2. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Goldberg D; French B; Abt P; Feng S; Cameron AM
Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
[TBL] [Abstract][Full Text] [Related]
3. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
[TBL] [Abstract][Full Text] [Related]
4. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Waitlist Mortality in Portopulmonary Hypertension.
DuBrock HM; Goldberg DS; Sussman NL; Bartolome SD; Kadry Z; Salgia RJ; Mulligan DC; Kremers WK; Kawut SM; Krowka MJ; Channick RN
Transplantation; 2017 Jul; 101(7):1609-1615. PubMed ID: 28207639
[TBL] [Abstract][Full Text] [Related]
6. Use of model for end-stage liver disease exceptions for donation after cardiac death graft recipients relisted for liver transplantation.
Maduka RC; Abt PL; Goldberg DS
Liver Transpl; 2015 Apr; 21(4):554-60. PubMed ID: 25597393
[TBL] [Abstract][Full Text] [Related]
7. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database.
Goldberg DS; Krok K; Batra S; Trotter JF; Kawut SM; Fallon MB
Gastroenterology; 2014 May; 146(5):1256-65.e1. PubMed ID: 24412528
[TBL] [Abstract][Full Text] [Related]
8. Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables.
Sher LS; Levi DM; Wecsler JS; Lo M; Petrovic LM; Groshen S; Ji L; Uso TD; Tector AJ; Hamilton AS; Marsh JW; Schwartz ME
J Surg Oncol; 2015 Aug; 112(2):125-32. PubMed ID: 26171686
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
10. Center variation in the use of nonstandardized model for end-stage liver disease exception points.
Goldberg DS; Makar G; Bittermann T; French B
Liver Transpl; 2013 Dec; 19(12):1330-42. PubMed ID: 24039090
[TBL] [Abstract][Full Text] [Related]
11. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation.
Leise MD; Kim WR; Kremers WK; Larson JJ; Benson JT; Therneau TM
Gastroenterology; 2011 Jun; 140(7):1952-60. PubMed ID: 21334338
[TBL] [Abstract][Full Text] [Related]
12. An Outcome-Based Approach to Assign MELD Exception Points for Patients With Hepatocellular Cancer.
Kensinger CD; Feurer ID; Karp SJ
Transplantation; 2017 Sep; 101(9):2056-2061. PubMed ID: 28471871
[TBL] [Abstract][Full Text] [Related]
13. Liver Transplantation for Hepatic Epithelioid Hemangioendothelioma Is Facilitated by Exception Points With Acceptable Long-term Outcomes.
Brahmbhatt M; Prenner S; Bittermann T
Transplantation; 2020 Jun; 104(6):1187-1192. PubMed ID: 31577674
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation.
Sundaram V; Jalan R; Wu T; Volk ML; Asrani SK; Klein AS; Wong RJ
Gastroenterology; 2019 Apr; 156(5):1381-1391.e3. PubMed ID: 30576643
[TBL] [Abstract][Full Text] [Related]
15. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
16. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
[TBL] [Abstract][Full Text] [Related]
17. Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation.
Raza MH; Kwon Y; Kobierski P; Misra AC; Lim A; Goldbeck C; Etesami K; Kohli R; Emamaullee J
Liver Transpl; 2023 Feb; 29(2):134-144. PubMed ID: 35876731
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes in liver transplant recipients with Model for End-stage Liver Disease scores of 40 or higher: a decade-long experience.
Panchal HJ; Durinka JB; Patterson J; Karipineni F; Ashburn S; Siskind E; Ortiz J
HPB (Oxford); 2015 Dec; 17(12):1074-84. PubMed ID: 26373873
[TBL] [Abstract][Full Text] [Related]
19. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
[TBL] [Abstract][Full Text] [Related]
20. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era.
Kim WR; Mannalithara A; Heimbach JK; Kamath PS; Asrani SK; Biggins SW; Wood NL; Gentry SE; Kwong AJ
Gastroenterology; 2021 Dec; 161(6):1887-1895.e4. PubMed ID: 34481845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
